Challenges in Treating Relapsed/Refractory Multiple Myeloma
20/09/2022, 20:00 – 21:00 hrs
The treatment of Relapsed, Refractory Multiple Myeloma (RRMM) can be complex. There is no general, gold, standard of treatment. Every single patient needs to be evaluated on many different factors.
Scientific program
20:00 –
20:05
Introduction
(Fredrik Schjesvold)
20:05 –
20:25
Patient case: Lenalidomide-refractory multiple myeloma at first relapse
(Inger Nijhof)
20:25 –
20:30
Challenging patient sub groups
(Fredrik Schjesvold)
20:30 –
20:50
Patient case: Early relapse following initial therapy for MM predicts poor outcome, even in the era of novel agents
(Isabelle Vande Broek)
20:50 –
20:55
Treatment implications and quality of life
20:55 –
21:00
Q&A with panel
Speakers
MD, PhD Fredrik Schjesvold
Hematologist,
Oslo Myeloma Center,
department of Hematology,
Norway
MD, PhD Inger Nijhof
Hematologist,
St. Antonius Hospital,
department of Internal Medicine,
The Netherlands
MD, PhD Isabelle Vande Broek
Hematologist,
Vitaz, Sint-Niklaas,
department of Oncology & Hematology,
Belgium
